Krystal BiotechFRA:4KB +2.29%58 PB Ratio is 8.09 as of Jun. 26, 2026, which is 44% above its 10-year median of 5.60. GuruFocus rates FRA:4KB with a GF Score™ of 58/100 and a GF Value™ of €263.13 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 1,232 Biotechnology companies, Krystal Biotech ranks worse than 83.2% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-26), Krystal Biotech's share price is €303.60. Krystal Biotech's Book Value per Share for the quarter that ended in Mar. 2026 was €37.52. Hence, Krystal Biotech's PB Ratio of today is 8.09.
Warning Sign:
Krystal Biotech Inc stock PB Ratio (=8.3) is close to 3-year high of 8.3.
The historical rank and industry rank for Krystal Biotech's PB Ratio or its related term are showing as below:
FRA:4KB'
s PB Ratio Range Over the Past 10 Years
Min: 3.67 Med: 5.6 Max: 8.3
Current: 8.3
During the past 10 years, Krystal Biotech's highest PB Ratio was 8.30. The lowest was 3.67. And the median was 5.60.
FRA:4KB's PB Ratio is ranked worse than 83.2% of 1232
companies
in the Biotechnology industry
Industry Median: 2.8
vs FRA:4KB: 8.30
During the past 12 months, Krystal Biotech's average Book Value Per Share Growth Rate was 27.30% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 27.30% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 20.40% per year.
During the past 10 years, the highest 3-Year average Book Value Per Share Growth Rate of Krystal Biotech was 45.60% per year. The lowest was 11.80% per year. And the median was 25.15% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Krystal Biotech PB Ratio Related Terms
Krystal Biotech PB Ratio Historical Data
* Premium members only.
The historical data trend for Krystal Biotech's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Krystal Biotech's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Krystal Biotech PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Krystal Biotech's PB Ratio distribution charts can be found below:
* The bar in red indicates where Krystal Biotech's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Krystal Biotech's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Krystal Biotech (FRA:4KB) has a PB Ratio of 8.09 as of Jun. 26, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Krystal Biotech and its competitors. This is 44% above median its historical median of 5.60. Over the past decade, Krystal Biotech's PB Ratio has ranged from 3.67 to 8.30. According to the industry distribution chart, Krystal Biotech ranks #1025 out of 1232 companies in the Biotechnology industry, placing it in the top 83.2%.
Is Krystal Biotech's PB Ratio too high?
Krystal Biotech's current PB Ratio of 8.09 is 44% above median its 10-year median of 5.60. Over the past 10 years, this metric has ranged from a low of 3.67 to a high of 8.30. The Biotechnology industry median PB Ratio is 2.80. Krystal Biotech's value of 8.09 is 188.9% above this industry median. Based on the distribution chart, Krystal Biotech ranks #1025 out of 1232 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Krystal Biotech has a GF Score™ of 58/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Krystal Biotech's PB Ratio compare to NUVL and PRAX?
According to the Biotechnology industry distribution chart, Krystal Biotech ranks #1025 out of 1232 companies for PB Ratio. This places Krystal Biotech in the lower half of its industry. The industry median PB Ratio is 2.80. Krystal Biotech's value of 8.09 is 188.9% above this benchmark. Historically, Krystal Biotech's own PB Ratio has ranged from 3.67 to 8.30 over the past decade. While the company's 10-year median is 5.60 vs. the industry median of 2.80, Krystal Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.80, based on 1,232 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Krystal Biotech's current PB Ratio of 8.09 is 188.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Krystal Biotech and its competitors. For the Biotechnology industry, the median PB Ratio is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Krystal Biotech's current PB Ratio is 8.09, which is 44% above median its own 10-year median of 5.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Krystal Biotech stock overvalued right now?
Based on GuruFocus' analysis, Krystal Biotech (FRA:4KB) is currently considered Modestly Overvalued. The stock's GF Value™ is €263.13, compared to a current price of €303.60 — trading 15.4% above its estimated fair value. The current PB Ratio is 8.09, which is 44% above median its 10-year median of 5.60 and 188.9% above the Biotechnology industry median of 2.80. Krystal Biotech's overall GF Score™ is 58/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Krystal Biotech (FRA:4KB), the current PB Ratio is 8.09 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Krystal Biotech (FRA:4KB) Overvalued in 2026?
Based on GuruFocus' analysis, Krystal Biotech stock appears to be overvalued.
The current stock price of €303.60 is trading 15.4% above its estimated GF Value™ of €263.13.
GuruFocus considers Krystal Biotech to be Modestly Overvalued.
Key valuation signals for FRA:4KB:
PB Ratio: 8.09 (44% above median its 10-year median of 5.60)
GF Value™: €263.13 vs. price of €303.60 (15.4% above fair value)
Industry Position: 188.9% above the Biotechnology median (#1025 of 1232)
No single metric tells the full story. See the FRA:4KB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
58GF Score
Get the complete analysis for FRA:4KB
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4KB has been successfully added to your 
